Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System - Pritpal Singh, Afrouz Nayernama, S Christopher Jones, Laleh Amiri Kordestani, Kath
Docetaxel is a microtubule inhibitor indicated for the treatment of multiple cancers as a single agent or in combination with other antineoplastics. The U.S. Fo...
Tatiana Prowell, MD
Review of #FDA AE Rep System (FAERS): 41 cases of fatal neutropenic enterocolitis (NE) w/ docetaxel. Notables: 66% after 1st dose, med to NE 7d & to death 9d, 22% despite growth factors. Most in #bcsm. Work of Drs. Pritpal Singh, Afrouz Nayernama, et al